

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Aragen Life Sciences files DRHP with SEBI for IPO

27 August 2026 | News

Capital expenditure to be incurred by Aragen Biologics towards purchase of new equipment and machinery



Aragen Life Sciences, a leading contract research, development and manufacturing organisation (CRDMO), has filed its draft red herring prospectus (DRHP) with SEBI for an initial public offering (IPO).

The IPO comprises a fresh issue of Rs 800 crore and an offer for sale (OFS) aggregating up to 27,329,192 equity shares of face value of Rs 10 each by selling shareholders.

The proceeds from the fresh issue are proposed to be utilised towards the repayment and/or pre-payment of borrowings; capital expenditure to be incurred by the company for purchase of new equipment and machinery for the company's facilities in Hyderabad; capital expenditure to be incurred by one of the company's material subsidiaries, Aragen Biologics Private Limited, for the facility in Bengaluru, towards purchase of new equipment and machinery; and general corporate purpose, supporting the company's next phase of expansion.

The company has become one of the top three largest Indian CRDMOs in terms of operating revenue among the assessed Indian peers, operating in a global CRDMO market estimated at \$171 billion in Fiscal 2026.